Brain+

0,01 DKK

+4,00 %

Mindre end 1K følgere

BRAINP

First North Denmark

Biotechnology & Pharmaceuticals

Health Care

Oversigt

Finansielt overblik og estimater

Ejerskab

Investorkonsensus

+4,00 %

-20,00 %

-21,21 %

-24,64 %

-77,70 %

-78,62 %

-98,43 %

-

-99,24 %

Brain + er aktiv i medicinalindustrien. Virksomheden har specialiseret sig i forskning og udvikling til behandling af demens og Alzheimers. Produktporteføljen omfatter f.eks. Kognitiv stimuleringsterapi. Forretningen drives med den største tilstedeværelse i Europa.

Markedsværdi

11,78 mio. DKK

Aktieomsætning

15,25 t DKK

Omsætning

200 t

EBIT %

-5.830 %

P/E

-

Udbytteafkast, %

-

Omsætning og EBIT-margin

Omsætning mio.

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Alle

Selskabsmeddelelser

Eksterne analyser

ViserAlle indholdstyper

Pressemeddelelsefor 14 timer siden

Brain+ Investor Update - November

Selskabsmeddelelse19.11.2025, 11.24

Brain+ A/S updates its financial guidance for 2025

Pressemeddelelse6.11.2025, 14.13

Brain+ investor update — October

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto

Følgere og notifikationer om fulgte virksomheder

Analytikerkommentarer og anbefalinger

Værktøj til at sammenligne aktier og andre populære værktøjer

Pressemeddelelse31.10.2025, 07.00

BRAIN+ UPDATES ITS COMMUNICATION POLICY AS THE COMPANY MOVES INTO A NEW COMMERCIALISATION PHASE

Selskabsmeddelelse6.10.2025, 06.20

Brain+ appoints new Chief Financial Officer

Pressemeddelelse24.9.2025, 06.36

Brain+ launches first Ayla NHS pilot with one of the UK’s largest primary care practices

Pressemeddelelse16.9.2025, 07.21

Brain+ signs agreement with Agincare Homes – the fourth UK care home group to deploy effective dementia therapy with Ayla

Selskabsmeddelelse15.9.2025, 09.41

The Chief Financial Officer to transition, replacement search has been initiated

Pressemeddelelse4.9.2025, 09.58

Clinical pilot of Ayla based dementia therapy (CST) improves cognitive outcome by nearly 50% in care home residents

Pressemeddelelse2.9.2025, 07.44

Brain+ expands its agreement with Southcare Homes Group to deploy Ayla across the group

Pressemeddelelse1.9.2025, 06.41

Brain+ invites investors and other stakeholders to a webinar for a presentation of its Half Year 2025 report

Selskabsmeddelelse28.8.2025, 21.23

Brain+ publishes Half Year Report for 2025

Selskabsmeddelelse24.6.2025, 12.11

Brain+ A/S announces first day of trading in new shares following the TO 5 warrant exercise

Selskabsmeddelelse18.6.2025, 09.22

Brain+ A/S announces the outcome of its series TO 5 warrant exercise

Selskabsmeddelelse10.6.2025, 07.58

Brain+ A/S has received commitments to cover 100% of its TO 5 warrants, securing DKK 5.9 million in gross proceeds

Pressemeddelelse6.6.2025, 14.56

Invitation to investor webinar featuring Antony Hall: How new CST evidence and UK dementia care quality focus underscore the relevance and potential of Ayla

Pressemeddelelse6.6.2025, 08.51

New research underscores the effects of Cognitive Stimulation Therapy, supporting its role for UK care homes to comply with care quality statements

Pressemeddelelse5.6.2025, 09.49

Brain+ signs agreement with UK care home group Majesticare deploying Ayla for effective dementia care

Selskabsmeddelelse2.6.2025, 13.49

Brain+ A/S announces the exercise price for its warrants of series TO 5

Selskabsmeddelelse30.5.2025, 14.22

Brain+ A/S - Minutes of Annual General Meeting

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.